Younossi Z M, Boparai N, McCormick M, Price L L, Guyatt G
Department of Gastroenterology, The Cleveland Clinic Foundation, Ohio, USA.
Am J Gastroenterol. 2001 Feb;96(2):579-83. doi: 10.1111/j.1572-0241.2001.03537.x.
Quantitative measures of the value patients place on the state of their health is crucial to understanding their experience, and to calculate quality-adjusted years of life for economic analyses. Patients' values in chronic liver disease remain unexplored, although experts' estimates of utilities have been examined. Our study tests the validity of a widely used utility measure in chronic liver disease and, if valid, establishes the decrement in health-related quality associated with chronic liver disease.
A total of 120 patients with chronic liver disease participated in the study (age 50 +/- 10 yr; men 53%; cirrhosis 51%, chronic viral hepatitis 51%, and chronic cholestatic liver disease 30%). All patients completed three instruments: Health Utility Index Mark 2 (scores 0-1), Short Form-36 (scale scores 0-100), and a disease-specific health-related quality of life instrument (Chronic Liver Disease Questionnaire; scores 1-7).
We found a moderate to strong correlation between scores on the three measures and that impairment worsened as the severity of disease worsened. Patients without cirrhosis and those with Child's A cirrhosis showed substantial decrement in utilities (0.82 and 0.83, respectively) in the range of patients surviving brain tumor. Those with Child's B and C showed a greater decrement (0.67 and 0.56) that was in the range experienced by patients who survive a stroke (0.67). Utilities assessed by Health Utility Index Mark 2 differed substantially from estimates by "expert."
We conclude that utilities should be based on patient reports and that the data from this study can inform economic analyses in studies of patients with chronic liver disease.
量化患者对自身健康状况的重视程度对于理解他们的体验以及计算用于经济分析的质量调整生命年至关重要。尽管已经对专家的效用估计进行了研究,但慢性肝病患者的价值观仍未得到探索。我们的研究测试了一种广泛使用的慢性肝病效用测量方法的有效性,如果有效,则确定与慢性肝病相关的健康相关质量的下降情况。
共有120例慢性肝病患者参与了该研究(年龄50±10岁;男性占53%;肝硬化占51%,慢性病毒性肝炎占51%,慢性胆汁淤积性肝病占30%)。所有患者均完成了三项测评工具:健康效用指数第二版(评分0 - 1)、简明健康调查问卷(量表评分0 - 100)以及一种特定疾病的健康相关生活质量测评工具(慢性肝病问卷;评分1 - 7)。
我们发现这三项测评工具的评分之间存在中度至强相关性,且随着疾病严重程度的加重,损害程度也随之恶化。无肝硬化患者以及Child's A级肝硬化患者的效用值大幅下降(分别为0.82和0.83),处于脑肿瘤存活患者的范围内。Child's B级和C级患者的效用值下降幅度更大(分别为0.67和0.56),处于中风存活患者的范围内(0.67)。健康效用指数第二版评估的效用值与“专家”估计值有很大差异。
我们得出结论,效用值应基于患者报告,并且本研究的数据可为慢性肝病患者研究中的经济分析提供参考。